Double homeobox protein 4 (DUX4) is characterized as a common driver of immune exclusion and contributes to a decreased objective response to anti-PD-L1 therapy in urothelial carcinoma patients [15]. The gene discussed is DUX4; the disease is urothelial carcinoma.